EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Genetic determinants of direct oral anticoagulant (DOAC) response: evidence, limitations and barriers to clinical implementation

Chameli Ratan, Uday Kumar, Shafiul Haque, Girish Thunga, Hisham Ahamed, Jecko Thachil, Vivek Nambiar

Expert Review of Clinical Pharmacology · 11.11.2026

DOI: 10.1080/17512433.2026.2762586 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 11.11.2026. Verfasst von Chameli Ratan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stroke Medicine, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, India. Die Arbeit nennt 117 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Direct oral anticoagulants (DOACs) offer predictable pharmacokinetics and simplified dosing compared with warfarin, yet clinically important inter-individual variability in drug exposure, efficacy, and safety persists. Pharmacogenomics can help explain this variability and advance precision anticoagulation. AREAS COVERED: This narrative review synthesizes evidence on genetic determinants of the pharmacokinetics and clinical outcomes of dabigatran, rivaroxaban, apixaban and edoxaban, identified by searching PubMed, Embase and Web of Science from inception to May 2026. Evidence from candidate-gene studies, genome-wide association studies, systematic reviews and meta-analyses was synthesized, and the magnitude of reported genetic effects were compared with the non-genetic determinants of exposure. Variants in CYP3A4, CYP3A5, CES1, ABCB1, and ABCG2 have been investigated for their potential effects on DOAC disposition and response. CES1 variants, particularly rs2244613, rs8192935, and rs71647871, may influence dabigatran exposure, while transporter variants may affect absorption and elimination. CYP3A4/5 and ABCG2 variation has also been associated with altered rivaroxaban and apixaban pharmacokinetics. Evidence for edoxaban, including SLCO1B1 variation, remains limited. EXPERT OPINION: Pharmacogenomics represents a promising component of individualized DOAC therapy, but routine clinical implementation is in progress. Prospective genotype-guided studies, validated polygenic and clinical-genetic scores, therapeutic concentration thresholds, and diverse multi‑ethnic validation are needed before pharmacogenomic testing can reliably inform DOAC selection and dosing.

Schlagwörter

Stichwörter der Autor:innen

CES1 enzymeCPIC guidelinesDirect oral anticoagulantsP-glycoproteincytochrome P450 enzymepharmacogenomicspolygenic risk scoresprecision medicine

Autor:innen und Institutionen

  • Department of Stroke Medicine, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, India.
  • Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi, India.
  • Department of Nursing, College of Nursing and Health Sciences, and Health Research Center, Jazan University, Jazan, Saudi Arabia.
  • School of Medicine, Universidad Espiritu Santo, Samborondon, Ecuador.
  • Department of Pharmacy Practice, Manipal Academy of Higher Education, Mangalore, India.
  • Department of Adult Cardiology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, India.

Zitieren

APA

Ratan, C., Kumar, U., Haque, S., Thunga, G., Ahamed, H., Thachil, J., & Nambiar, V. (2026). Genetic determinants of direct oral anticoagulant (DOAC) response: evidence, limitations and barriers to clinical implementation. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2026.2762586

Vancouver

Ratan C, Kumar U, Haque S, Thunga G, Ahamed H, Thachil J, et al. Genetic determinants of direct oral anticoagulant (DOAC) response: evidence, limitations and barriers to clinical implementation. Expert Review of Clinical Pharmacology. 2026. doi:10.1080/17512433.2026.2762586

BibTeX
@article{Ratan2026,
  author = {Ratan, Chameli and Kumar, Uday and Haque, Shafiul and Thunga, Girish and Ahamed, Hisham and Thachil, Jecko and Nambiar, Vivek},
  title = {Genetic determinants of direct oral anticoagulant (DOAC) response: evidence, limitations and barriers to clinical implementation},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2026},
  doi = {10.1080/17512433.2026.2762586}
}
Kostenlos starten →